News
ALKS
51.60
-0.52%
-0.27
Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)
TipRanks · 1d ago
Alkermes Is Maintained at Buy by Needham
Dow Jones · 1d ago
Alkermes Price Target Raised to $62.00/Share From $61.00 by Needham
Dow Jones · 1d ago
Needham Maintains Buy on Alkermes, Raises Price Target to $62
Benzinga · 1d ago
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study
Benzinga · 1d ago
American Express, Biogen upgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
Thome Reiterates Buy on Encouraging Alixorexton Data and Reduced Oxybate Competition, Lifting Price Target to $57
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Conmed (CNMD) and Alkermes (ALKS)
TipRanks · 1d ago
Alkermes Price Target Announced at $60.00/Share by JP Morgan
Dow Jones · 1d ago
Alkermes Says Interim Analysis From Ogoing Long-term Extension Study Of Alixorexton For Narcolepsy Showed Sustained Clinically Meaningful Improvement In Wakefulness
Benzinga · 1d ago
Alkermes announces results from planned interim analysis of LTE of alixorexton
TipRanks · 1d ago
Alkermes says alixorexton sustains wakefulness gains in nine-month narcolepsy extension study interim analysis
PUBT · 1d ago
JP Morgan Reinstates Neutral on Alkermes, Announces $60 Price Target
Benzinga · 1d ago
Weekly Report: what happened at ALKS last week (0706-0710)?
Weekly Report · 1d ago
Analysts’ Top Healthcare Picks: Conmed (CNMD), Alkermes (ALKS)
TipRanks · 1d ago
Alkermes resumed with a Neutral at JPMorgan
TipRanks · 1d ago
Bank of America Securities Remains a Sell on Alkermes (ALKS)
TipRanks · 1d ago
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Barchart · 1d ago
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Immunome (IMNM)
TipRanks · 5d ago
Is Alkermes (ALKS) Fully Priced As Russell 2000 Index Inclusion Draws Fresh Attention?
Simply Wall St · 5d ago
More
Webull provides a variety of real-time ALKS stock news. You can receive the latest news about Alkermes Plc through multiple platforms. This information may help you make smarter investment decisions.
About ALKS
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.